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Abstract
Background: Ephrin A1 (EFNA1) is a member of the A-type ephrin family of cell surface proteins that function as
ligands for the A-type Eph receptor tyrosine kinase family. In malignancy, the precise role of EFNA1 and its
preferred receptor, EPHA2, is controversial. Several studies have found that EFNA1 may suppress EPHA2-mediated
oncogenesis, or enhance it, depending on cell type and context. However, little is known about the conditions
that influence whether EFNA1 promotes or suppresses tumorigenicity. EFNA1 exists in a soluble form as well as a
glycophosphatidylinositol (GPI) membrane attached form. We investigated whether the contradictory roles of
EFNA1 in malignancy might in part be related to the existence of both soluble and membrane attached forms of
EFNA1 and potential differences in the manner in which they interact with EPHA2.
Results: Using a RNAi strategy to reduce the expression of endogenous EFNA1 and EPHA2, we found that both
EFNA1 and EPHA2 are required for growth of HeLa and SK-BR3 cells. The growth defects could be rescued by
conditioned media from cells overexpressing soluble EFNA1. Interestingly, we found that overexpression of the
membrane attached form of EFNA1 suppresses growth of HeLa cells in 3D but not 2D. Knockdown of endogenous
EFNA1, or overexpression of full-length EFNA1, resulted in relocalization of EPHA2 from the cell surface to sites of
cell-cell contact. Overexpression of soluble EFNA1 however resulted in more EPHA2 distributed on the cell surface,
away from cell-cell contacts, and promoted the growth of HeLa cells.
Conclusions: We conclude that soluble EFNA1 is necessary for the transformation of HeLa and SK-BR3 cells and
participates in the relocalization of EPHA2 away from sites of cell-cell contact during transformation.
Background
The Eph receptors are the largest family of receptor tyr-
osine kinases. They are activated by protein ligands,
known as ephrins, which are attached to the cell mem-
brane by either a membrane-spanning protein domain
(B-type) or by a glycosylphosphatidylinositol (GPI)
anchor (A-type). The receptors are also divided into A
and B classes according to the type of ephrin they bind
and their sequence similarity. Typically, the Eph A
receptors bind to A-type ephrins, and Eph B receptors
bind to B-type ephrins. However, binding between
classes does occur with certain family members [1,2].
The functions regulated by Eph receptors and their
ephrin ligands are diverse and cell-type dependent. They
control a large number of physiological and develop-
mental processes, and have also been implicated in both
the suppression and advancement of cancer (reviewed
in [3]).
Perhaps the best characterized, in terms of its pro- and
anti-oncogenic roles, is EPHA2. EPHA2 confers tumori-
genic and metastatic potential to non-transformed breast
and skin epithelial cells, as well as mouse fibroblasts, and
is overexpressed in tumor parenchyma of several cancers,
including breast, bladder, prostate, colon, eosophageal,
ovarian, cervical, stomach, and melanoma [4-12]. This
ability to transform fibroblasts and some epithelial cell
types, as well as its high expression levels in several dif-
ferent types of cancer, suggests that EPHA2 may have a
direct role in oncogenesis. Independent reports support
this hypothesis. For example, analysis of EPHA2 knock-
out mice revealed that EPHA2 enhances ErbB2-mediated
tumorigenesis in MMTV-Neu mammary tumor mouse
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models [13]. As well, EPHA2 knockout mice are deficient
in their ability to support the invasion and metastasis of
implanted tumors, likely through a defect in angiogenesis
[14]. In contrast to this pro-oncogenic role for EPHA2,
EPHA2 knockout mice are more susceptible to chemi-
cally-induced skin cancer, which indicates that in some
circumstances EPHA2 can suppress tumorigenesis [15].
However, little is known about what factors determine
whether EPHA2 augments or suppresses cancer
progression.
One feature that appears to distinguish oncogenic
EPHA2 from the tumor suppressive form is its cellular
localization. In non-transformed cells, EPHA2 is loca-
lized primarily to cell-cell junctions. Conversely, in
transformed cells, EPHA2 is distributed on the cell sur-
face and is localized to membrane ruffles [4,16-19]. The
localization of EPHA2 and stability of adherens junc-
tions are intimately linked. Ephrin stimulation of
EPHA2 activity in normal epithelial cells enhances cell-
cell adhesions by suppressing Arf6 GTPase and loss of
E-cadherin results in EPHA2 mislocalization [16,19].
Conversely overexpression of EPHA2 increases the turn-
over of E-cadherin cell adhesions in a RhoA dependent
manner and leads to EPHA2 mislocalization [17]. Thus
the localization of EPHA2 correlates functionally with
its roles in growth suppression and oncogenesis.
One of the contextual factors affecting EPHA2 trans-
formation is likely the expression of its preferred ligand,
EFNA1. EFNA1 is often co-expressed in tumors along
with EPHA2 [7,20-25] EFNA1 can both inhibit and sti-
mulate oncogenesis, depending on the cellular context.
In some cell types, such as glioblastoma multiforme
cells, EFNA1 expression downregulates EPHA2 and sup-
presses EPHA2-mediated oncogenesis [26,27]. Indeed,
stimulation of certain EPHA2 overexpressing cancer cell
lines with recombinant EFNA1-Fc fusion proteins has
been shown to suppress oncogenesis by causing receptor
internalization [4,27-29] and in normal epithelial cells
EFNA1 functions at cell-adhesions to stabilize E-cad-
herin adhesion complexes [19]. However, the suppres-
sive effects of EFNA1 are not ubiquitously observed and
several studies have supported a pro-oncogenic role for
EFNA1. There are many cancers and cancer cell lines
that overexpress both EPHA2 and EFNA1, including
bladder and ovarian cancer, which indicates that EFNA1
expression does not always lead to EPHA2 downregula-
tion [24,25]. As an example, in HT29 colorectal cancer
cells, Potla et al. (2002) showed that endogenous EFNA1
is required for the growth in semi-solid media of these
EPHA2 positive cells [23]. A positive role in promoting
cancer has been confirmed experimentally in transgenic
mice overexpressing EFNA1 in the intestinal mucosa,
where EFNA1 enhances malignant progression in
Apcmin/+mice [30]. Therefore, the ability of EFNA1 to
suppress or contribute to EPHA2-mediated oncogenesis
appears to be contextual and cell-type dependent. How-
ever, the exact physiological conditions that elicit tumor
suppression or oncogenesis remain elusive.
In addition to the GPI-linked membrane bound form of
EFNA1, EFNA1 is also shed from the cell surface through
the action of lipases and metalloproteases [7,21,31]. In
fact, soluble EFNA1 is present in conditioned media
from numerous cancer cell lines and was originally
described as a soluble angiogenic factor induced by
TNFa [21,32,33]. Until recently, this soluble pool of
EFNA1 was thought to be inactive. This assumption was
based on early studies that showed that ephrins require
membrane attachment and higher-order clustering to
stimulate Eph receptor activity [34]. Recently, however, it
has been shown that soluble monomeric EFNA1 can acti-
vate EPHA2 activity [31]. This study supports the early
work of Bartley et al.(1994) which showed that EFNA1
purified from conditioned media could induce EPHA2
phosphorylation and was important for TNFa induced
angiogenesis [7,21,33]. The existence of a soluble iso-
form, in addition to a membrane attached isoform,
implies that EFNA1 can also function at a distance away
from immediate cell-cell contacts. We reasoned that the
reported contradictory effects of EFNA1 in malignancy
might in part be related to the existence of both soluble
and membrane attached forms of EFNA1 and potential
differences in the manner in which they interact with
EPHA2.
To address this issue, we used RNAi to reduce EFNA1
expression in HeLa and SK-BR3 cells, which express
both EPHA2 and EFNA1 endogenously, and also pro-
duce a soluble isoform of EFNA1. Here we show that
soluble EFNA1 is necessary for the growth of these
cells. In addition, we show that soluble EFNA1 contri-
butes to the EPHA2 relocalization from sites of cell-cell
contact to the cell surface, which occurs during epithe-
lial cell transformation.
Results
To examine the role of endogenous soluble and mem-
brane bound EFNA1 in the context of EPHA2 oncogen-
esis, we chose HeLa cells, an aggressive cervical cancer
cell line that expresses both EPHA2 and EFNA1 (Figure
1c, 2c). To determine the function of endogenous EFNA1
expression, we first developed shRNA directed against
EFNA1. Hairpin oligos targeting two different sequences
of human EFNA1 were generated and cloned into a
mammalian expression vector. Expression of the shRNAs
reduced the expression of an exogenously expressed
EFNA1, confirming the ability of the shRNA to target
EFNA1 (Figure 1a,b). To determine whether the endo-
genous EFNA1 was attached to the cell surface or
released, conditioned media and lysates were prepared
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from cultured cells. Conditioned media was collected
after 48 hours of incubation, concentrated 20-fold (to
approximately same volume as lysates), and analyzed by
Western blot. A 25 kDa band corresponding to EFNA1
was detected in the cellular lysates, as well as in the con-
ditioned media from HeLa cells (Figure 1c). To confirm
that this band corresponded to EFNA1, we knocked
down EFNA1 expression in HeLa cells using shRNA.
Transfection of shRNA directed against EFNA1
decreased the expression of EFNA1 in both the lysates
and conditioned medium as expected (Figure 1c). In the
conditioned media from HeLa cells, we also detected two
high molecular weight bands at approximately 50 kDa
and 200 kDa (Figure 1c). Soluble EFNA1 has been
reported to be a substrate for tissue transglutaminase,
which covalently oligomerizes the soluble A-type ephrins
[35]. However, we did not detect a decrease in the levels
of these proteins following shRNA transfection, suggest-
ing that they represent non-specific antibody binding
rather than oligomerized forms of EFNA1. Our finding of
EFNA1 in the conditioned media of HeLa cells indicates
that, like many cancer cells, HeLa cells express EFNA1 in
addition to EPHA2, and that some of the EFNA1 is
released from the cell surface of these cells. The existence
of soluble EFNA1 in HeLa cells raises the possibility that
it can affect EPHA2 signaling.
Although it is known that EPHA2 can transform sev-
eral cell types, the role of EFNA1 in this process is not
known. The inherent co-expression of both EPHA2 and
EFNA1 in HeLa cells gave us the opportunity to address
the role of endogenous EFNA1 in EPHA2-mediated
oncogenic signaling. We characterized the effect of
EFNA1 knockdown on the growth of HeLa cells in semi-
solid media. Growth in semi-solid media is a characteris-
tic trait of most cancer cells, and is widely used as an in
vitro measure of tumorigenicity [36]. Knockdown of
EFNA1 reduced the ability of HeLa cells to grow in semi-
solid medium (Figure 2a, b). This result indicates that
EFNA1 is required for the anchorage independent
growth of HeLa cells. To knockdown EPHA2, commer-
cially available short interfering RNA (siRNA) duplexes
were used. For comparison purposes, siRNA duplexes
targeting the identical sequences as the EFNA1 shRNA
were also generated. Similar to the effects observed for
EFNA1 knockdown, siRNA-mediated knockdown of
EPHA2 reduced the level of expression of EPHA2 in
HeLa cells (Figure 2c) and inhibited the ability of the
cells to grow in semi-solid medium (Figure 2d). These
results indicate that, like HT29 colon carcinoma cells,
HeLa cells require both EFNA1 and EPHA2 for ancho-
rage independent growth [23].
We next examined the effects of EFNA1 knockdown
on growth in two dimensions (2D). We observed that
a decrease in EFNA1 expression reduced the growth of
Figure 1 Knockdown of exogenous and endogenous EFNA1.
For exogenous knockdown of EFNA1, HeLa cells were transiently
transfected with EFNA1 cDNA and with either empty vector control,
EFNA1 shRNA#1, or EFNA1 shRNA#2 plasmids. A) Western blot of 3
independent experiments showing the typical level of knockdown
of exogenous EFNA1 (top). Blot was stripped and reprobed with an
anti-b-actin antibody to show equal loading between lanes. B)
Quantification of knockdown showing the average expression of
EFNA1 relative to the amount of b-actin +/- the standard deviation.
C) Endogenous EFNA1 knockdown. HeLa cells were transiently
transfected with either empty vector control, or EFNA1 shRNAi#1.
Shown are duplicate transfections. Western blotting using an anti-
EFNA1 antibody showed a knockdown of endogenous EFNA1 in
both conditioned medium and lysates (arrow). Below is a western
blot using anti-Grb2 which was used to confirm equal loading of
lysate lanes. * shows two cross-reacting bands which were used to
confirm equal loading of conditioned medium lanes.
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HeLa cells in 2D (Figure 3a). Unlike the results of
Potla et al. (2002) using HT29 cells, the effect on
growth did not appear to be density dependent [23].
We did not detect an increase in apoptosis, indicating
that EFNA1 is required for the growth of HeLa cells
but not for survival (Figure 3b). To test whether this
requirement for EFNA1 is restricted to HeLa cells, we
also knocked down EFNA1 in SK-BR3 cells. These
cells are an invasive breast epithelial cancer cell line
that express soluble EFNA1 at high levels (Figure 3c,d)
[21]. Similar to HeLa cells, knockdown of EFNA1 in
SK-BR3 cells caused a decrease in cell proliferation
(Figure 3e,f). Since most of the EFNA1 in these cells is
found in the media, this result suggests that soluble
EFNA1 is required to promote the growth of these
cancer cells.
Figure 2 Knockdown of EFNA1 and EPHA2 suppresses growth in semi-solid medium. A) HeLa cells were transfected with pcDNA3 empty
vector control, EFNA1 shRNA1, EFNA1 shRNA2. Transfected cells were plated in 0.5% agarose and allowed to grow for two weeks. Shown are
ten representative fields for each transfection. B) Quantification of growth in semi-solid medium. Results represent the average number of
colonies +/- standard deviation from three independent experiments each plated in quadruplicate. C) Western blot of knockdown of
endogenous EPHA2 showing typical knockdown of using siRNA directed against EPHA2 (Top). Below is the same blot reprobed with anti-b-actin,
which was used to confirm equal loading between lanes. D) Quantification of growth in semi-solid medium as above. In this case, HeLa cells
were transfected with siRNAs against EFNA1 or EPHA2.
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Figure 3 EFNA1 is required for growth of HeLa and SK-BR3 cells. A) HeLa cells were plated at low density and transfected with either
scrambled siRNA, a universal non-silencing siRNA, or EFNA1 siRNA. Growth was monitored over a 72 hour period using crystal violet staining.
B) Knockdown of EFNA1 with siRNA1 or siRNA2 did not affect apoptosis levels in HeLa cells and were comparable to scrambled siRNA treated
cells. Shown is a representative histogram of AnnexinV staining on transfected cells 24 hours after transfection. Camptothecin treatment was
used as a positive control for apoptosis. C) Western blot of endogenous EFNA1 expression in SK-BR3 cell lysates and conditioned media from
these cells. D) Western blot of EFNA1 showing band detected in conditioned media is not present in media alone. E) Western blot of SK-BR3
cells transfected with EFNA1 siRNA. Below is the same blot reprobed with anti-b-actin, which was used to confirm equal loading between lanes.
F) SK-BR3 cells were plated at low density and transfected with either, non-silencing siRNA, or 3 different EFNA1 siRNA. Growth was monitored
over a 72 hour period using crystal violet staining.
Alford et al. Cancer Cell International 2010, 10:41
http://www.cancerci.com/content/10/1/41
Page 5 of 13
To test the hypothesis that soluble EFNA1 is necessary
for growth of HeLa cells, we determined if soluble
EFNA1 was sufficient to rescue the growth of HeLa cells
in 2D. Conditioned media from HeLa cells, EFNA1
knockdown cells, or HeLa cells stably transfected with a
truncated version of EFNA1 (lacking the C-terminal
sequence necessary for GPI anchor attachment) were col-
lected and used to treat either vector control HeLa cells,
or the HeLa cells in which EFNA1 expression has been
stably knocked down. As shown in Figure 4a, expression
of the truncated EFNA1 increases the amount of soluble
EFNA1 in the media, and therefore provides an enriched
source of soluble EFNA1. Conditioned media from cells
overexpressing soluble EFNA1 rescued the growth of
EFNA1 knockdown cells as well as enhanced the growth
of the vector control cells (Figure 4b). Next we tested
whether soluble EFNA1 collected from the overexpres-
sing cells was sufficient to rescue growth in semi-solid
media of EFNA1 knockdown cells. Treatment of knock-
down cells with conditioned media from soluble EFNA1
overexpressing cells partially rescued anchorage indepen-
dent growth. We suspected that the inability of the solu-
ble EFNA1 to completely rescue the growth in semi-solid
agarose was due to limited amounts of EFNA1 in the
conditioned media. In our rescue of the 2D growth of
EFNA1 knockdown lines, we observed that growth was
improved when the conditioned media was changed fre-
quently. This was not feasible with the prolonged culture
time of the 3D experiments. In support of this, treating
cells with EFNA1-Fc fusion protein (1 μg/ml) rescued
the growth in semi-solid agarose of EFNA1 knockdown
cells (Figure 4d). These results show that soluble EFNA1
is necessary for the growth of HeLa cells in both 2D
and 3D.
To explore whether there are differences in the signal-
ing properties of soluble and membrane bound EFNA1,
we overexpressed full-length EFNA1, or soluble EFNA1,
in HeLa cells and compared the ability of the transfected
cells to grow in 2D. This experiment was based on the
fact that the expression of the full length construct did
not significantly increase the amount of soluble EFNA1
(Figure 4A). Overproduction of soluble EFNA1 pro-
moted the growth of HeLa cells in 2D whereas overex-
pression of full length EFNA1 had no effect, which
confirms that soluble EFNA1 has pro-growth effects on
these cells (Figure 4e). Interestingly, expression of full-
length EFNA1 suppressed the ability of HeLa cells to
grow in semi-solid medium (Figure 4f). Cells expressing
soluble EFNA1 appeared to be intermediate between the
control and full-length EFNA1. This suggests overpro-
duction of soluble EFNA1 may be slightly inhibitory,
although this effect was not statistically significant (Fig-
ure 4f). These results indicate that overproduction of
EFNA1 inhibits anchorage independent growth.
In normal epithelial cells, EPHA2 and membrane
bound EFNA1 engage in reciprocal signaling at cell-cell
contacts and are important for maintaining adherens
junctions [4,16,17,37]. In transformed cells overexpres-
sing EPHA2, the receptor destabilizes adherens junc-
tions and is mislocalized to membrane ruffles and to
distinct punctae on the surface of the cell [4,16,17,37].
Delocalized EPHA2 is thought to signal in a ligand-inde-
pendent fashion and lead to transformation. However,
the possible contribution of soluble EFNA1 to this pro-
cess has not been examined. To investigate this ques-
tion, we first examined the cellular localization of
EPHA2 in control and EFNA1 knockdown cells. In con-
trast to control-transfected cells, where EPHA2 had a
more punctuate appearance on the cell surface and loca-
lized to membrane ruffles (Figure 5A,B), EPHA2 was
primarily localized to cell-cell junctions and the periph-
eral membrane in EFNA1 knockdown cells (Figure 5C,
D). EFNA1 localization in control cells also showed a
punctate appearance and co-localized with EPHA2 on
the cell surface and membrane ruffles. This pattern was
reduced in shRNA treated cells confirming that localiza-
tion was specific for EFNA1 and not the cross reacting
proteins. We also examined the localization of EPHA2
in cells overexpressing either full-length EFNA1 or trun-
cated EFNA1. In cells expressing full-length EFNA1
(Figure 6A, B), EPHA2 was enriched at cell-cell contacts
and the peripheral membrane. In contrast, in cells
overexpressing truncated EFNA1, EPHA2 and EFNA1
localization was more diffuse and was not enriched at
cell-cell contacts (Figure 6C, D). This shows that
EFNA1 is important for EPHA2 localization in these
transformed cells, and suggests a mechanism whereby
release of EFNA1 from the cell surface participates in
the relocalization of EPHA2 during oncogenesis in some
cell types.
Collectively, our results show that soluble EFNA1 is
required for EPHA2-mediated oncogenesis in HeLa cells
and affects the relocalization of EPHA2 from sites of
cell-cell contact which occurs during EPHA2 mediated
transformation.
Discussion
It has been known since the early 90’s that many cancer
cell lines shed EFNA1 from their cell surface [21]. How-
ever, the significance of this has been unclear. Although
this early work showed that EFNA1 from the condi-
tioned media of cell lines was able to activate EphA
kinase activity, subsequent contradictory work showing
the apparent inability of soluble monomeric ephrin to
activate Eph receptors led to the widespread generaliza-
tion in the literature that ephrins must be membrane
bound to signal [1,34,38-40]. The recent confirmation
that soluble monomeric EFNA1 can activate EPHA2
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Figure 4 Transfection of HeLa cells with full length EFNA1 (A1) or a truncated EFNA1 lacking the C-terminal signal for GPI anchor
attachment (A1-ve GPI). Shown is an anti-EFNA1 western blot of lysates and conditioned media. Truncated EFNA1 accumulates in the
conditioned medium whereas the full-length EFNA1 does not. B) Soluble EFNA1 in conditioned media rescues the growth of EFNA1 knockdown
cells. HeLa cells stably transfected with either vector control or shRNA against EFNA1 were grown in conditioned media from either vector
control or knockdown cells (own CM) or conditioned media from cells in which truncated soluble EFNA1 is overexpressed (A1-veGPI CM). C)
Soluble EFNA1 in conditioned media partially rescues the growth of EFNA1 knockdown cells in semi-solid media. HeLa cells stably transfected
with either vector control or shRNA against EFNA1 were grown in semi solid media that was supplemented with either conditioned media from
either vector control or knockdown cells (own CM) or conditioned media from cells in which truncated EFNA1 is overexpressed (A1-veGPI CM).
D) EFNA1-Fc rescues the growth of EFNA1 knockdown cells in semi-solid media. HeLa cells stably transfected with either vector control or
shRNA against EFNA1 were grown in semi media that was supplemented with either EFNA1-Fc (A1Fc) or Fc alone. E) Overexpression of soluble
EFNA1 (EFNA1-GPI) but not full length EFNA1 promotes the growth of HeLa cells. HeLa cells were stably transfected with pcDNA3, EFNA1 full
length, or truncated EFNA1-GPI. Pools of stable clones were then counted, seeded at low density, and growth was monitored by crystal violet
staining. F) Overexpression of EFNA1 inhibits the growth of HeLa cells in semi-solid media. The stable pools of HeLa cells described above were
plated at the same density in semi-solid media and the number of colonies determined after two weeks of growth.
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suggests that soluble EFNA1 has the ability to signal
beyond cell-cell contacts [31]. Indeed, our results show
that soluble EFNA1 is important for transformation, and
is a positive growth signal in HeLa and SK-BR3 cells.
This provides evidence that the production the produc-
tion of soluble EFNA1, at least some cancer cells lines,
has physiological relevance.
A second controversial aspect of EFNA1 signaling in
cancer cells is whether the protein promotes or inhibits
oncogenesis. Our work provides some insight into the
seemingly disparate ability of the same protein to both
positively and negatively regulate oncogenesis. Within a
single cell type we have found EFNA1 can promote or
inhibit cell growth depending on whether it is presented
in the conditioned media or membrane attached, and on
expression levels. Specifically, overexpression of full length
EFNA1 inhibited anchorage independent growth but had
no effect on growth in 2D. Overexpression of soluble
EFNA1 had little effect on growth in 3D but promoted
growth in 2D. When soluble EFNA1 was provided in the
Figure 5 Localization of EFNA1 and EPHA2 in knockdown and control cells. HeLa cells were transfected with empty vector (pcDNA),
shRNA1 against EFNA1 (shRNA) and the localization of EPHA2 and EFNA1 was determined. Shown are representative images. In control
cells (pcDNA A and B), EFNA1 and EPHA2 colocalize on the dorsal surface of the cell and to membrane ruffles (arrows) with very little expression
at cell-cell contacts. In EFNA1 knockdown cells (shRNA A1 C and D), EPHA2 was localized primarily to cell-cell contacts (arrowhead) at the
peripheral membrane. Bar represents 5 μm.
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conditioned media it had a positive role in the growth of
cells in both 2D and 3D. This result indicates that the
amount and whether it is presented in its membrane
attached or soluble form contribute to whether EFNA1 is
inhibitory or pro-oncogenic. Overproduction may interfere
with EPHA2 trafficking or block EPHA2 interaction
with soluble EFNA, especially when EFNA1 is membrane
attached. Collectively, our results suggest that produc-
ing moderate levels of soluble EFNA1 in these EPHA2-
positive cells promotes growth and transformation.
Further work is required to determine how applicable
these results are to other cancer cells that express soluble
EFNA1. However, our finding that soluble EFNA1 is
required for the growth of both a cervical and breast can-
cer cell line suggests that the positive role of soluble
EFNA1 in promoting the growth of cancer cells is not
restricted to one cell line or cell type. Indeed the recent
finding that EFNA1 is found in the serum of patients with
hepatocellular carcinoma, suggests that soluble EFNA1 is
also relevant for in situ cancer [20].
Figure 6 Localization of EFNA1 and EPHA2 in cells overexpressing EFNA1. In cells transfected with full length EFNA1 (A1 FL A and B),
EPHA2 strongly colocalized with EFNA1 at cell-cell contacts (arrows) and exhibited less cell surface staining. In cells transfected with truncated
soluble EFNA1 (A1-veGPI C and D), EPHA2 and EFNA1 colocalized to the dorsal surface of cells and were not enriched at cell-cell junctions.
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The localization of EPHA2 away from cell-cell con-
tacts is correlated with its transformation properties
[16,17]. Our results show that soluble EFNA1 is impor-
tant for this relocalization in HeLa cells. In cells
deficient for EFNA1 or over-expressing full length mem-
brane bound EFNA1, EPHA2 returns to sites of cell-cell
contact and is no longer transforming. Whereas in cells
overexpressing soluble EFNA1, the localization of
EPHA2 resembles that of wild-type HeLa cells, and is
not enriched at cell-cell contacts. These results suggest
that soluble EFNA1 is involved in the relocalization of
EPHA2 during transformation. One possibility is that
soluble EFNA1 competes for binding of other ephrins to
EPHA2 at cell-cell contacts and thereby draws EPHA2
away from cell contacts. If membrane bound EFNA1 is
important for anchoring EPHA2 at cell-cell contacts and
soluble EFNA1 relocalizes EPHA2 away from these sites,
what causes EPHA2 to return to cell-cell contacts in
EFNA1 knockdown cells? We have found that HeLa
cells also express ephrin A2 and A4 (data not shown).
Therefore, EPHA2 localization may be restored through
an interaction with these ephrins. However, further
work is required to determine how soluble EFNA1 con-
tributes to EPHA2 localization and signaling, and to test
these possibilities.
Ephrins and Eph receptors have well established roles
at cell-cell contacts that are necessary for such develop-
mental processes as tissue compartmentalization, axon
guidance, and angiogenesis. Our results show that in
addition to these important roles in signaling between
adjacent cells, EFNA1 also has the ability to signal at a
distance through the production of a soluble non-mem-
brane attached isoform. It will be interesting to deter-
mine whether signaling by soluble EFNA1 has any roles
during normal development as well as to elucidate
further its role in promotion of cancer.
Conclusions
There have been contradictory findings with regard to
whether EFNA1 is pro- or anti-oncogenic and whether
soluble EFNA1 is functional. We have shown that
within a single cancer cell line EFNA1 has both pro and
anti-oncogenic properties and that this behavior is influ-
enced by whether EFNA1 is membrane attached or not,
and the amount of EFNA1 produced. Soluble EFNA1 is
important for the growth of two cancer cell lines and
contributes to the relocalization of EPHA2 away from
cell-cell contacts which accompanies transformation.
We conclude that the ability of cancer cells to release
EFNA1 is an important step in EPHA2-mediated trans-
formation in a subset of cancer cells. To our knowledge,
this is the first study to show that endogenous soluble
EFNA1 positively contributes to the growth of cancer
cells and to demonstrate that the physiological effects of
EFNA1 signaling are not limited to cell-cell contacts.
Methods
Cell culture, transfection and RNA interference
HeLa cells were maintained in Dulbecco’s Modified Eagle’s
Medium with 10% fetal bovine serum (FBS), 5% CO2 at
37°C. SK-BR3 cells were maintained in McCoy’s 5A modi-
fied media + 10% FBS, 5% CO2 at 37°C. For EFNA1
knockdowns, siRNA and shRNA were designed to three
EFNA1 specific sequences: (1) P5’UGAGGACUACAC-
CAUACAU GU3’ (human specific), (2) 5’GAAGGACA-
CAGCUACUACUAC3’(mouse and human) and (3) p5
UCCACAGGAGAAGAGACUU3’(human). siRNA target-
ing of EFNA1 was achieved by purchasing duplex RNA
molecules containing these sequences from Sigma (Saint
Louis, MO). For shRNA experiments, the following cDNA






gaaagtagtagctgtgtccttcg-3’). These oligos contain 19 bases
of sense and anti-sense strands of human ephrin A1 sepa-
rated by a loop sequence, and flanked at either end by
restriction enzyme sites. A terminator sequence was added
to the 3’ end, in between the antisense sequence and the 3’
restriction site. The above oligos were annealed
(A1RNAiF1+ A1RNAiR1; A1RNAiF2+A1RNAiR2) and
cloned into KpnI and EcoRI sites, downstream of an H1
promoter, which had been inserted into a pcDNA3 back-
bone in which the CMV promoter had been deleted. All
constructs were confirmed by sequencing. HeLa cells were
transiently transfected with either short hairpin RNA
(shRNA) containing plasmids using Lipofectamine
Reagent (Invitrogen) following the manufacturer’s instruc-
tions or with siRNA duplexes using Hiperfect Reagent
(Qiagen, Carlsbad CA) according to the manufacturer’s
instructions. For the generation of stable colonies, trans-
fected cells were split (1:10) and G418 (400 μg/ml) resis-
tant colonies were selected. For EPHA2 knockdowns,
siRNAs targeting EPHA2 were purchased and transfected
with Hiperfect transfection reagent as per the manufac-
turer’s instructions (Qiagen, Carlsbad CA). As a control
for the siRNA experiments either AllStar Negative siRNA
AF546 (Qiagen, Carlsbad CA) or a scrambled duplex of
the above EFNA1-1 sequence was employed. EFNA1-GPI
was PCR amplified from full length human EFNA1 cDNA
using the following primers: Forward-tcggatccatg-
gagttcctctgggc; Reverse-tcgaattcaccgatgctatgtagaac. The
product was gel purified, digested with BamHI and EcoRI
and ligated into the BamHI/EcoRI sites in pcDNA3 using
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standard techniques. This creates a truncated EFNA1
which lacks the GPI anchor attachment sequence and is
constitutively secreted.
Western blots and immunofluorescence
Antibodies used for western blots and immunofluores-
cence were anti-EFNA1 (anti-mouse EFNA1 Sigma, clone
E7150 and anti-human EFNA1 (Santa Cruz), anti-bactin
(Sigma, clone A1978, Saint Louis MO), anti-EPHA2
(clone D7, Upstate, Lake Placid NY). The anti-mouse
EFNA1 antibody was used to detect exogenous EFNA1
whereas the anti-human EFNA1 antibody detected the
endogenous EFNA1. For western blots, HeLa or SK-BR3
cells were lysed in NP-40 lysis buffer (20 mM Tris pH
8.0, 137 mM NaCl, 10% glycerol, 1% nonidet-P40, 2 mM
EDTA) with Protease Inhibitor Cocktail (P8465 Sigma,
Saint Louis MO). Lysates were incubated on a gyrator for
20 minutes at 4°C and then centrifuged at 14000 rpm for
10 minutes at 4°C. The soluble fraction was separated by
SDS-PAGE and transferred to nitrocellulose. The blot
was blocked with Tris-buffered saline (TBS)-TWEEN20
(0.1%) with 5% skim milk powder and probed with pri-
mary antibody overnight at 4°C. Blots were washed three
times five minutes with TBS-TWEEN (0.1%) followed by
a one hour incubation with secondary antibody in TBS-
TWEEN20 (0.1%). After three washes, blots were devel-
oped using ECL Plus detection system (GE Healthcare,
Buckinghamshire UK) following manufacturer’s instruc-
tions. Relative expression was determined using ImageJ
(NIH) software densitometry analysis in comparison to
b-actin levels.
Immunofluorescence localization was performed under
non permeablilizing conditions on HeLa cells plated on 4
chamber Labtek Permanox slides (Nalgene NUNC, Naper-
ville, IL). Forty-eight hours after transfection, cells were
gently washed twice with phosphate buffered saline (PBS).
Cells were fixed using 3% formaldehyde, 1% sucrose in
PBS for 30 minutes. Cells were then washed three times
with PBS and blocked for 1 hour at room temperature
with 3% BSA in PBS. After two washes with PBS, cover-
slips were incubated with primary antibody for one hour.
After six washes with PBS, coverslips were incubated with
secondary antibody for one hour. Slides were then washed
six times with PBS and twice with dH2O prior to counter
staining with 1 μM Hoechst 33342 (Molecular Probes,
Eugene OR) for 1 minute. Coverslips were washed with
dH20, and mounted using ProLong Antifade mounting
media (Molecular Probes, Eugene OR).
Semi-solid agar assays
Anchorage-independent colony formation was analyzed
in semi-solid agarose assays. HeLa cells were mixed
(3000 cells/24 well) with 500 μl of 0.25% (w/v) warmed
agarose in DMEM with 10% FBS (complete media). This
layer was plated onto a bottom layer of complete med-
ium/agarose (0.5%). For rescue experiments, plates were
incubated at 37°C, 5% CO2 and each day the media was
replaced with either conditioned media (100 μl condi-
tioned media + 100 μl of fresh DMEM 10% FBS) that
was previously prepared from the same population or
conditioned media (100 μl conditioned media + 100 μl
of fresh DMEM 10% FBS) from HeLa cells overexpres-
sing EFNA1-ve GPI (soluble EFNA1). The rescue with
recombinant EFNA1 used EFNA1-Fc (EA1-Fc) and Fc
at 1 μg/ml in complete media and was exchanged as
above. Colonies were examined with Leica DM IRM
inverted light microscope and analysed using OpenLab
5.0 Software. Wells were divided into a 12 position grid
and the number colonies were counted at each position.
Alternatively, the media was drawn off, and the agarose
was heated at 65°C for 5 min to dissolve the agarose
and the colonies were counted using a hemocytometer.
For the conditioned media rescue, data represent the
average from three independent experiments from two
independent EFNA1 knockdown clones +/- the standard
deviation. A one way ANOVA (F(3,44) = 51.70, p <
.001) followed by a Bonferroni’s multiple comparison
post test was used to determine whether the observed
differences in average number of colony coverage
between groups were significant. For the A1-Fc rescue,
data represent the average from four independent
experiments on one clone +/- the standard deviation. A
one way ANOVA (F(3,8) = 13.89, p < 0.0015) followed
by a Bonferroni’s multiple comparison posttest was used
to determine whether the observed differences between
A1-Fc and Fc alone treated cells were significant.
For the overexpression of EFNA1 experiment, HeLa
cells were transfected with pcDNA3, full-length EFNA1,
or soluble EFNA -ve GPI. The next day, the transfected
cells were split (1:10) and G418 (400 μg/ml) resistant
colonies were selected. After approximately 1 week of
selection the colonies were pooled together by trypsiniz-
ing, counted and plated as above in semi-solid media.
The data represent the average number of colonies from
four independent transfections +/- the standard devia-
tion. A one way ANOVA (F2,9) = 5.897, p < 0.023) fol-
lowed by a Bonferroni’s multiple comparison posttest
was used to determine whether the observed differences
between vector treated cells and EFNA1 overexpressing
cells were significant.
Cell growth assay
Zero, twenty-four, forty-eight, and seventy-two hours
following transfection, relative cell number was assayed
by crystal violet staining. Cells were washed once with
PBS and fixed with 10% formalin for 10 minutes at
room temperature. Cells were washed two times with
dH2O and incubated with 0.1% crystal violet for
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30 minutes at room temperature. To remove excess
stain, cells were washed with dH2O. Crystal violet was
extracted using 10% acetic acid. Extracts were diluted
1:4 and their absorbance was measured at 595 nm using
a VictorV 1420 Multilabel plate reader. Data represents
the average growth from three independent experiments
averaged from two independent EFNA1 knockdown
clones +/- the standard deviation. Error bars represent
the standard deviation. A two way ANOVA (F(3,80) =
42.28, p < .001) followed by a Bonferroni post test was
used to determine whether the observed differences at
each time point were significant. In all cases, the growth
of the knockdown cells was diminished by 72 hours in
comparison to control or rescued cells (p < .001).
Apoptosis assay
HeLa cells were transiently transfected as described
above. At 24 hours post-transfection, cells were scraped
and pelleted, washed once in PBS, and resuspended in
1× Annexin Binding buffer (FITC Annexin V Apoptosis
Detection Kit, BD Pharmigen). Cells were stained for
flow cytometry using Annexin V-FITC and Propidium
Iodide according to manufacturer’s instructions (BD
Pharmigen) and sorted on a BD FACSCalibur system
(BD Biosciences). As a positive control for apoptosis,
cells were treated for four hours with camptothecin
(4 μg/ml) and processed as above.
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